idea fragments, which were then accumulated into unique idea resumes against each barrier and ultimately refined into 12 idea platforms. Five of those platforms were identified as having the strongest potential for resolving major challenges and were developed into emergent, actionable strategies (Figure 3-5).
Sims explained how the five strategies might address their respective barriers in the SLD supply chain:
• Case Tracker: A mobile-enabled incident-reporting and treatment system to pool data, stimulate action, track demand for care, and enable more detailed forecasting.
• Global Connect: A mobile, Web-based system to support HCP adherence to recommended treatment and improve delivery of care.
• TB Impact Network: A moderated network of global efforts to treat and prevent TB and MDR TB and to improve collaboration.
• Health Express: A Web-based product-tracking and procurement support system to improve QA SLD supply chain visibility.
• New TB “Brand”: Development of a consolidated voice or campaign for MDR TB to drive accountability and heighten awareness of the urgency of MDR TB nationally and internationally.
a This box is based on the presentations by Michael Kimerling, Senior Program Officer, Tuberculosis Global Health Program, BMGF, and Tracy Sims, Vice President, Eli Lilly & Co. Foundation.
b Partners included the Eli Lilly & Co. Foundation, the Stop TB Partnership, and the Innosight Consulting Firm.
• Current barriers in access to SLDs include a lack of demand, inflexibility and a mismatch of expectations from stakeholders, and country capacity barriers.
• Collective inability to consolidate demand and a lack of collaboration among stakeholders, including funders, are key barriers to an effective SLD supply chain.